Prescribing behaviour after the introduction of decentralized drug budgets: Is there an association with employer and type of care facility?

Scandinavian Journal of Primary Health Care

Volumn 27, Issue 2, 2009, Pages 117-122

  Andersson, Karolina ^a   Carlsten, Anders ^b,c   Hedenrud, Tove ^b  

^a NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c Apoteket AB   (Sweden)

Author keywords

Cost containment; Drug budget; Physicians; Prescribing patterns; Sweden

Indexed keywords

ANTIDEPRESSANT AGENT; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; ROFECOXIB; SEROTONIN UPTAKE INHIBITOR; DRUG;

AMBULATORY CARE; ARTICLE; CLINICAL PRACTICE; DRUG COST; EMPLOYER; HEALTH CARE COST; HEALTH CARE FACILITIES AND SERVICES; PRESCRIPTION; PRIMARY HEALTH CARE; RANK SUM TEST; SWEDEN; BUDGET; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; GENERAL PRACTICE; HUMAN; ORGANIZATION AND MANAGEMENT;

BUDGETS; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG PRESCRIPTIONS; FAMILY PRACTICE; HUMANS; PHARMACEUTICAL PREPARATIONS; PHYSICIAN'S PRACTICE PATTERNS; PRIVATE SECTOR; PUBLIC SECTOR; SWEDEN;

EID: 66149127305     PISSN: 02813432     EISSN: 15027724     Source Type: Journal    
DOI: 10.1080/02813430902793225     Document Type: Article

References (18)

1. Andersson K, Petzold MG, Sonesson C, Lönnroth K, Carlsten A. Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002. Health Policy 2006; 79:231-43.
2. Andersson K. Swedish pharmaceutical benefit reforms: analyses of implementation, pharmaceutical sales patterns and expenditures. Göteborg: Göteborg University; 2006.
3. Andersson K, Jorgensen T, Carlsten A. Physicians' opinions and experiences of the Pharmaceutical Benefits Reform. Scand J Public Health 2006;34:654-9.
4. Buusman A, Andersen M, Merrild C, Elverdam B. Factors influencing GPs' choice between drugs in a therapeutic drug group. A qualitative study. Scand J Prim Health Care 2007; 25:208-13.
5. Skoglund I, Segesten K, Bjorkelund C. GPs' thoughts on prescribing medication and evidence-based knowledge: The benefit aspect is a strong motivator. A descriptive focus group study. Scand J Prim Health Care 2007;25:98-104.
6. Avery AJ, Wetzels RV, Rodgers S, O'Neill C. Do GPs working in practice with high or low prescribing costs have different views on prescribing cost issues? Br J Gen Pract 2000;50:100-4.
7. Reichert S, Simon T, Halm EA. Physicians' attitudes about prescribing and knowledge of the costs of common medications. Arch Intern Med 2000;160:2799-803.
8. Ryan M, Yule B, Bond C, Taylor RJ. Do physicians' perceptions of drug costs influence their prescribing? Pharmacoeconomics 1996;9:321-31.
9. Ashworth M, Golding S, Majeed A. Prescribing indicators and their use by primary care groups to influence prescribing. J Clin Pharm Ther 2002;27:197-204.
10. Wettermark B, Tomson G, Bergman U. [Quality indicators for drug prescribing - the situation in Sweden]. Lakartidnin-gen 2006;103:3607-11.
11. Williams D, Bennett K, Feely J. The application of prescribing indicators to a primary care prescription database in Ireland. Eur J Clin Pharmacol 2005;61:127-33.
12. Håkansson A, Andersson H, Cars H, Melander A. Prescribing, prescription costs and adherence to formulary committee recommendations: Long-term differences between physicians in public and private care. Eur J Clin Pharmacol 2001;57:65-70.
13. Bower AD, Burkett GL. Family physicians and generic drugs: A study of recognition, information sources, prescribing attitudes, and practices. J Fam Pract 1987;24: 612-6.
14. Tamblyn R, McLeod P, Hanley JA, Girard N, Hurley J. Physician and practice characteristics associated with the early utilization of new prescription drugs. Med Care 2003; 41:895-908.
15. Melville A, Mapes R. Anatomy of disaster: The case of practolol. In: Mapes REA, editor., Prescribing practice and drug usage London: Croom Helm; 1980. p. 121-140.
16. Bergstrom G, Karlberg I. Decentralized responsibility for costs of outpatient prescription pharmaceuticals in Sweden: Assessment of models for decentralized financing of subsidies from a management perspective. Health Policy 2007; 81:358-67.
17. Jansson S, Anell A. The impact of decentralised drug-budgets in Sweden: A survey of physicians' attitudes towards costs and cost-effectiveness. Health Policy 2006;76: 299-311.
18. Vallano A, Montane E, Arnau JM, Vidal X, Pallares C, Coll M, et al. Medical speciality and pattern of medicines prescription. Eur J Clin Pharmacol 2004;60:725-30.